Kezar Life Sciences, Inc. (KZR)

Market Cap	63.13M
Revenue (ttm)	7.00M
Net Income (ttm)	-87.79M
Shares Out	72.69M
EPS (ttm)	-1.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	721,245
Open	0.881
Previous Close	0.893
Day's Range	0.863 - 0.919
52-Week Range	0.670 - 7.890
Beta	0.38
Analysts	Buy
Price Target	11.00 (+1,166.7%)
Earnings Date	Nov 13, 2023

About KZR

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is zetomipzomib (KZR-616), a selective immunoproteasome inhibitor that is in Phase 2b clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; Phase 1b clinical trials in systemic lupus erythematosus; and completed Phase 2a clinical trials ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 21, 2018
• Employees: 84
• Stock Exchange: NASDAQ
• Ticker Symbol: KZR

Analyst Forecast

According to 4 analysts, the average rating for KZR stock is "Buy." The 12-month stock price forecast is $11.0, which is an increase of 1,166.70% from the latest price.

Price Target

$11.0

(1,166.70% upside)

Analyst Consensus: Buy